老年糖尿病医防融合的研究进展

doi:10.3969/j.issn.1003-9198.2023.07.004

摘要/Abstract

中图分类号:

王逸飞, 李铭麟, 张飞, 王佳贺. 老年糖尿病医防融合的研究进展[J]. 实用老年医学, 2023, 37(7): 658-661.

[1] 王欣荣, 李强翔, 杨芳. 老年糖尿病管理标准的研究进展 [J]. 中国临床保健杂志, 2023, 26(1): 135-139.
[2] CHO N H, SHAW J E, KARURANGA S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045 [J]. Diabetes Res Clin Pract, 2018, 138: 271-281.
[3] XU Y, WANG L, HE J, et al. Prevalence and control of diabetes in Chinese adults [J]. JAMA, 2013, 310(9): 948-959.
[4] 张晓琳, 刘珉, 李钢, 等. 不同管理模式对2型糖尿病患者血糖控制达标率的影响 [J]. 中国医药导报, 2019, 16(3): 53-56,70.
[5] DIXON D L, CARBONE S. Screening, identification, and management of prediabetes to reduce cardiovascular risk: a missed opportunity? [J]. Diabetes Metab Res Rev, 2020, 36(6): e3316.
[6] WANG J, SHEN X, HE S, et al. Hypertriglyceridaemia predicts subsequent long-term risk of cardiovascular events in Chinese adults: 23-year follow-up of the Daqing Diabetes Study [J]. Diabetes Metab Res Rev, 2019, 35(6): e3163.
[7] 《中国老年2型糖尿病防治临床指南》编写组. 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中国糖尿病杂志, 2022, 30(1): 2-51.
[8] HAW J S, GALAVIZ K I, STRAUS A N, et al. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials [J]. JAMA Intern Med, 2017, 177(12): 1808-1817.
[9] 潘琦, 郭立新. 《中国老年糖尿病诊疗指南(2021年版)》要览 [J]. 中国医学前沿杂志:电子版, 2022, 14(4): 1-6, 69.
[10] Introduction: Standards of Medical Care in Diabetes-2018 [J]. Diabetes Care, 2018, 41(Suppl 1): S1-S2.
[11] Fats and fatty acids in human nutrition. Report of an expert consultation [R]. FAO Food Nutr Pap, 2010, 91: 1-166.
[12] KNOWLER W C, BARRETT-CONNOR E, FOWLER S E, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin [J]. N Engl J Med, 2002, 346(6): 393-403.
[13] YKI-JÄRVINEN H. Thiazolidinediones [J]. N Engl J Med, 2004, 351(11): 1106-1118.
[14] DEFRONZO R A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 [J]. Diabetologia, 2010, 53(7): 1270-1287.
[15] BISCHOFF H. The mechanism of alpha-glucosidase inhibition in the management of diabetes [J]. Clin Invest Med, 1995, 18(4): 303-311.
[16] CHIASSON J L, JOSSE R G, GOMIS R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial [J]. JAMA, 2003, 290(4): 486-494.
[17] SHIMABUKURO M, TANAKA A, SATA M, et al. α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study [J]. Cardiovasc Diabetol, 2017, 16(1): 86.
[18] MAHAFFEY K W, NEAL B, PERKOVIC V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study) [J]. Circulation, 2018, 137(4): 323-334.
[19] FEDEWA M V, GIST N H, EVANS E M, et al. Exercise and insulin resistance in youth: a meta-analysis [J]. Pediatrics, 2014, 133(1): e163-e174.
[20] THORP A A, KINGWELL B A, SETHI P, et al. Alternating bouts of sitting and standing attenuate postprandial glucose responses [J]. Med Sci Sports Exerc, 2014, 46(11): 2053-2061.
[21] American Diabetes Association Professional Practice Committee. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022 [J]. Diabetes Care, 2022, 45(Suppl 1): S39-S45.
[22] JIANG L, JOHNSON A, PRATTE K, et al. Long-term outcomes of lifestyle intervention to prevent diabetes in American Indian and Alaska Native communities: The Special Diabetes Program for Indians Diabetes Prevention Program [J]. Diabetes Care, 2018, 41(7): 1462-1470.
[23] HAMMAN R F, WING R R, EDELSTEIN S L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes [J]. Diabetes Care, 2006, 29(9): 2102-2107.
[24] 赵林雪. 糖尿病健康管理模式的研究进展 [J]. 中国城乡企业卫生, 2020, 35(1): 40-422.
[25] 李锐, 施亮, 杨群娣, 等. 上海市社区管理2型糖尿病患者血糖控制和用药情况 [J]. 环境与职业医学, 2016, 33(4): 329-333.
[26] 侯春梅. 全科医学治疗在2型糖尿病患者疾病治疗过程中的效果研究[J]. 实用糖尿病杂志, 2019, 15(4): 24.
[27] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [J]. Lancet, 1998, 352(9131): 837-853.
[28] NATHAN D M, GENUTH S, LACHIN J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [J]. N Engl J Med, 1993, 329(14): 977-986.
[29] NATHAN D M, CLEARY P A, BACKLUND J Y, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes [J]. N Engl J Med, 2005, 353(25): 2643-2653.

Metrics

阅读次数

全文

1108

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	1108

下载来源	本网站	其他网站

次数	818	290
比例	74%	26%

摘要

110

最新录用	在线预览	正式出版

0	0	110

	下载来源	其他网站

	次数	110
	比例	100%